Platelet Disorders in Companion Animals

Reviews
Shared by: Amna Khan
Stats
views:
401
rating:
not rated
reviews:
0
posted:
5/3/2008
language:
English
pages:
0
Platelet Disorders in Companion Animals Julien Dandrieux Internal Medicine Resident Louisiana State University jdandrieux@mail.vetmed.lsu.edu Objectives Become familiar with clinical presentations of platelet disorders  tests for evaluation of platelet disorders  Identify diseases causing primary hemostasis defect thrombocytopenia  thrombocytopathy  Von Willebrand’s disease (vWD)  Definitions  Hemostasis: arrest of the escape of blood (primary and secondary hemostasis) Thrombocytopenia: decrease in number of platelets in circulating blood Thrombocytopathy: any qualitative disorder of blood platelets   H E M O S T A S I S Primary Platelets Tissue factors Secondary Coagulation factors Clinical Presentation Clinical Presentation Most common clinical sign is bleeding of some sort  External loss  Epistaxis, hematuria, GI bleeding  Internal loss — skin, mucous membranes, retina  Petechiae, ecchymosis, hematoma Manifestations of platelet disorders Clinical Presentation Most common clinical sign is bleeding in some form  External loss  Epistaxis, hematuria, GI bleeding  Internal loss — skin, mucous membranes, retina  Petechiae, ecchymosis, hematoma Manifestations of platelet disorders Manifestations of platelet disorders Evaluation of bleeding disorders Evaluation of bleeding disorders  History  Vaccination, drug, infection  CBC with differential and platelet count  Manual count important if clumping, large platelets Coagulation panel (PT, PTT), BMBT, vWF concurrent disease, hematuria Platelet production, concurrent disease  Hemostasis   Chemistry panel, Urinalysis   [Bone marrow]  Evaluation of Bleeding Disorders Test Platelet count Parameter Platelet quantity Normal Function 1ary hemostasis BMBT vWF assay Platelet function vWF 1ary hemostasis 1ary hemostasis PTT PT Coagulation (in.) Coagulation (ex.) 2ary hemostasis 2ary hemostasis Evaluation of Bleeding Disorders Test Platelet count Parameter Platelet quantity Normal Function 1ary hemostasis BMBT vWF assay Platelet function vWF 1ary hemostasis 1ary hemostasis PTT PT Coagulation (in.) Coagulation (ex.) 2ary hemostasis 2ary hemostasis Platelet count (CBC) Platelet count  Falsely decreased: clumping (C), large platelets (C) Platelet morphology   Mean platelet volume (MPV) Platelet distribution width (PDW) Platelet estimate  10-30 platelets per 100x fields Severe bleeding with 0-3 platelets per 100x fields Platelet morphology CLUMPING ITP, IMHA Buccal mucosal bleeding time (BMBT) Information about platelet function! Normal: 1.8 to 4.2 minutes Platelets and bleeding Low platelet number = Thrombocytopenia  < 50,000/ml  Below 25,000-30,000/ml is critical point VS Platelet dysfunction = Thrombocytopathy Thrombocytopenia Most commonly recognized hematological disorders in veterinary medicine Thrombocytopenia Decrease production Sequestration Increased utilization Destruction Decreased production Various causes  Marrow aplasia /myelofibrosis  Marrow infiltrate—neoplasia  Marrow suppression—drug, infection, toxin Bone marrow aspiration  Decreased megakaryocytes (MK) (aspiration/core)  Usually other cell lines are also affected Decreased production Treat the underlying disease if possible  Remove drug source  Treat infection  Treat neoplasia Supportive care (no injuries!!) Thrombocytopenia Decrease production Increased utilization Sequestration Destruction Bone marrow disease - Infection - Toxin - Drug - Neoplasia Sequestration Hypersplenism  Platelet mass is normal, but platelets are sequestered in the spleen  Occurs secondary to splenomegaly due to immune-mediated disease, neoplasia, infectious disease  Clinical significance? No MK increase because no decrease in platelet mass Thrombocytopenia Decrease production Increased utilization Sequestration Destruction MK diminished - Infection - Toxin - Drug - Neoplasia MK normal - Possible endotoxemia - Drug? - Clinical relevance? Increased Utilization Severe blood loss  Trauma  Mild thrombocytopenia (up to 120,000/ml)  Anemia, hypoalbuminemia, hypovolemic choc Disseminated intravascular coagulopathy (DIC)  Secondary (neoplasia, liver disease, pancreatitis)  Chemistry, PT, PTT, D-dimers, ATIII Increased Utilization MK: adequate or hyperplasia in most cases Treatment  Severe blood loss Fluids, blood products + surgery  DIC Treating underlying disease Plasma Thrombocytopenia Decrease production Increased utilization Sequestration Destruction MK diminished - Infection - Toxin - Drug - Neoplasia MK normal - Possible endotoxemia - Drug? - Clinical relevance? MK normal/increased - Blood loss - DIC Destruction Immune mediated thrombocytopenia (ITP)  Primary  autoantibody directed against antigen on the platelet membrane  Secondary Most common cause of thrombocytopenia  Associated with underlying condition: Systemic autoimmune disease, neoplasia, infection, vaccination  Primary ITP—Clinic Breed  Cocker spaniel  GSD  Poodles Usually young to middle-aged dogs  F >> M Can remain asymptomatic!! Primary ITP—Laboratory Severe Thrombocytopenia (<30,000/ml) Increase proportion of small or large platelets Anti-platelet antibody MK  Usually hyperplasia  Decreased if also antibodies against MK  Antimegakaryocyte antibody test Primary ITP—Treatment Exclusion of secondary causes Immunosuppression  Corticosteroids, azathioprine, cyclosporine  (Cyclophosphamide, vincristine??) Platelet rich plasma Splenectomy  Spleen is primary site of platelet removal  Does not correct underlying cause Secondary ITP—Causes Drug induced  Sulfa antibiotics, estrogen, acetaminophen, phenylbutazone Infectious agents  Viral (FeLV, parvovirus),  Rickettsial (Ehrlichia spp., RMSF, Mycoplasma)  Bacterial (Leptospira, Salmonella)  Protozoal (Babesia, Leishmania, Toxoplasma, Cytauxzoon spp.)  Fungal (Histoplasma capsulatum, Candida albicans) Secondary ITP—Causes Other immune-mediated diseases  Systemic lupus erythematosus Vaccinations (modified live vaccines, transient) Neoplasia (Rule out DIC, bone marrow involvement!)  Lymphoma  Multiple myeloma Secondary ITP—Treatment Remove inciting cause  Discontinue drug therapy Treat the underlying disease  Antibiotics, antifungals  Chemotherapy, surgery, RT  Immunosuppression Thrombocytopenia Decrease production Increased utilization Sequestration Destruction MK diminished - Infection - Toxin - Drug - Neoplasia MK normal - Possible endotoxemia - Drug? - Clinical relevance? MK normal/increased - Blood loss - DIC MK normal/decreased - Primary - Secondary Thrombocytopathy Thrombocytopathy Decreased function of platelets despite adequate platelet number  Platelet count often normal, may even be increased  Clinically detectable bleeding may occur at any platelet count  Megakaryocytes usually normal to increased Clinical Evaluation Buccal mucosal bleeding time  Perform in cases with normal coagulation times, normal platelet count, but clinical evidence of bleeding or past coagulation issues  Prolonged in cases of platelet dysfunction Classification Congenital  Von Willebrand factor (vWF)  Platelet membrane/granule abnormality Acquired  Drugs  Systemic disease Congenital disorders  von Willebrand’s disease (vWD)  Most common inherited disorder of hemostasis  Glanzman’s thrombopathia Otterhounds  Great Pyrenees    Basset Hound thrombopathia Scott syndrome von Willebrand’s disease  vWf function  Platelet aggregation Decrease number and normal structure   Cause  Type I Type II Type III Dobermann, Airedale Terrier, Rottweiller German Wirehair, Shorthair Pointers Shetland Sheepdog, Chesapeake Bay Ret.  Decrease number and abnormal structure   Absolute vWf deficiency  von Willebrand’s disease Laboratory findings     Platelet number: PT, PTT: BMBT: vWf concentration: NORMAL NORMAL PROLONGED DECREASED von Willebrand’s disease Treatment  Screen predisposed breeds prior to surgical procedures   BMBT vWf immunoassay   Fresh frozen plasma prior surgery Desmopressin-administered SQ prior to surgery Acquired : Drug induced       NSAIDs Anesthetics (halothane) Antibiotics (penicillin, cephalothin) Calcium channel blockers (diltiazem) Anticoagulants (heparin) Many others… Acquired : systemic disease      Uremia Monoclonal gammopathy DIC Hepatic disease Neoplasia Conclusions  Primary hemostasis testing   Platelet count (-penia) BMBT (-pathy)  Thrombocytopenia    Most common acquired haemostatic disorder Decrease production/sequestration/utilization/destruction Bleeding, petechiae and ecchymoses  Von Willebrand’s disease    Example of thrombocytopathy (BMBT) Most common inherited disorder of hemostasis Common in Doberman Questions?

Related docs
Platelet
Views: 19  |  Downloads: 7
Platelet Brochure.CMYK 0708
Views: 11  |  Downloads: 0
] Disorders of Hemostasis
Views: 250  |  Downloads: 45
Section-4-Circulatory-Disorders
Views: 0  |  Downloads: 0
Section-4-Circulatory-Disorders
Views: 0  |  Downloads: 0
Mood Disorders in the Elderly
Views: 1  |  Downloads: 0
Hematologic Disorders
Views: 323  |  Downloads: 16
premium docs
Other docs by Amna Khan
Wandering spleen
Views: 800  |  Downloads: 33
Variation of Spleen Size in College Age Athletes
Views: 602  |  Downloads: 2
THYMIC TUMORS - General Thoracic Surgery
Views: 626  |  Downloads: 32
Thymic malignancies and other mediastinal tumors
Views: 853  |  Downloads: 57
TCVM Food Therapy for Gastrointestinal Disorders
Views: 609  |  Downloads: 13
Stomach and spleen
Views: 1409  |  Downloads: 45
Spleen Injuries Contusion and Laceration
Views: 2498  |  Downloads: 36
Spleen - Ultrasound Technique.
Views: 839  |  Downloads: 40
She has tuberculosis of peripheral lymph nodes
Views: 507  |  Downloads: 8
Osseous Tissue and Bone Structure
Views: 1375  |  Downloads: 27
Myeloproliferative disorders Dr Tariq Roshan
Views: 237  |  Downloads: 27